Srividhya, M (2016) Efficacy and Usefulness of SGLT2 Inhibitors in Niddm Patients on the Backdrop of Metformin and Sulphonyl Urea. Masters thesis, Periyar College of Pharmaceutical Sciences, Tiruchirappalli.
|
Text
260703116srividhya.pdf Download (2MB) | Preview |
Abstract
INTRODUCTION: Diabetes is a chronic condition that occurs when the body cannot produce enough insulin or cannot use insulin, and is diagnosed by observing raised levels of glucose in the blood. Insulin is a hormone produced in the pancreas; it is required to transport glucose from the bloodstream into the body’s cells where it is used as energy. The lack, or ineffectiveness, of insulin in a person with diabetes means that glucose remains circulating in the blood. Over time, the resulting high levels of glucose in the blood (known as hyperglycaemia) causes damage to many tissues in the body, leading to the development of disabling and life-threatening health complications. PREDIABETES: Before people develop type 2 diabetes or non-insulin dependent diabetes mellitus (NIDDM), they almost always have "prediabetes" blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. Doctors sometimes refer to prediabetes as impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), depending on what test was used when it was detected. This condition puts the patients at a higher risk for developing type 2 diabetes and cardiovascular disease. GENETICS OF TYPE 2 DIABETES: Type 2 diabetes has a stronger link to family history and lineage than type 1, although it too depends on environmental factors. Studies of twins have shown that genetics play a very strong role in the development of type 2 diabetes. Lifestyle also influences the development of type 2 diabetes. Obesity tends to run in families, and families tend to have similar eating and exercise habits. If you have a family history of type 2 diabetes, it may be difficult to figure out whether your diabetes is due to lifestyle factors or genetic susceptibility. Most likely it is due to both. AIM OF THE STUDY: To study the effectiveness of Sodium-Glucose Transport 2 Inhibitors (SGLT2 inhibitors) in patients with type 2 diabetes mellitus on the background treatment with metformin and a sulphonyl urea OBJECTIVES: To assess the glycaemic control by observing: 1. Fasting blood sugar, 2. Post-prandial blood sugar, 3. Glycosylated haemoglobin (HbA1c), 4. Reduction in body weight. CONCLUSION: 1. This study included 105, T2DM patients of which, patients in the age group of 21 to 30 yrs on one end and 71 to 80 yrs on the other were a bare minimal on both the groups. Further the social habits, food habits being a vegan or nonvegetarian were also equally distributed amongst the two groups. About familial history of Diabetes with the patients, it was 73% in Group A and 72% in Group B. Patients with normal weight were 22% in Group A and 16% in Group B of the Body Mass Index. 5% patients were under Class III category of obesity in Group A whereas it was 6% in Group B. All the above parameters are placed of equal distribution, thereby variables are kept at a bare minimum not jeopardizing the observed results in any way. 2.F. P. G. values showed a reduction of 5.7% from base value in Group A; whereas the same was showing a significant 34.64% reduction in Group B patients 3.The post prandial glucose measurement showed a 6.79% reduction in Group A and 34.58% reduction in Group B patients. 4.The HbA1c values showed a 2.59%reduction in Group A and a very significant 7.28% reduction in Group B cases. 5.Ultimately the reduction in Body Mass Index was 1.57%in Group A and 6.28% in Group B patients. 6.The outcome of this study clearly shows that addition of a SGLT2 inhibitor drug to the conventional oral regime of type II diabetes with metformin and a sulphonyl urea has a marked and significant advantage over the biguanide + sulphonyl urea only combination considering all the parameters that showa better and significant control of the blood glucose level and the Body Mass Index. 7.Hence T2DM may conveniently be treated with metformin and a sulphonyl urea with the addition of a SGLT2 Inhibitor for a significantly improved life of patients.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg. No.261440151 |
| Uncontrolled Keywords: | SGLT2 Inhibitors ; Niddm Patients ; Backdrop ; Metformin ; Sulphonyl Urea. |
| Subjects: | PHARMACY > Pharmacy Practice |
| Depositing User: | Ravindran C |
| Date Deposited: | 12 Apr 2018 05:19 |
| Last Modified: | 12 Apr 2018 06:39 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/6945 |
Actions (login required)
 |
View Item |
